Atezolizumab plus targeted drug for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have liver cancer (hepatocellular carcinoma) confirmed by tests, and it must be advanced and not curable
- Have already tried atezolizumab plus bevacizumab as first treatment and your cancer grew after that (second-line patients only)
- Be able to return to the study clinic for follow-up during active treatment
- Have good enough blood counts and liver function (reviewed by recent blood tests)
- Have certain hepatitis virus test results (hepatitis B and C screening) and meet the study’s rules for active hepatitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus targeted proton radiation for liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors and improve outcomes for people with intermediate or advanced stage liver cancer.
This study looks at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer in real life, outside of a clinical trial. It will help doctors understand the treatment's benefits and risks based on patient records.
Hear when a new Locally Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.